{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE322nnn/GSE322507/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322507"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"MELK inhibition promotes megakaryopoiesis and platelet recovery in immune thrombocytopenia through ERK–cofilin signaling","description":"Maternal embryonic leucine zipper kinase (MELK) has been implicated in cell-cycle regulation, yet its transcriptional programs in megakaryocytic cells remain incompletely defined. To profile MELK-dependent gene expression changes, we performed bulk RNA-seq on the human megakaryoblastic cell line MEG-01 transduced with a control pLKO.1 vector or a MELK-targeting shRNA (sh2-MELK), with three independent biological replicates per condition. Paired-end sequencing reads (raw FASTQ files) and processed gene-level expression quantifications are provided to support differential expression and pathway analyses of MELK knockdown in megakaryocytic cells.","dates":{"publication":"2026/04/02"},"accession":"GSE322507","cross_references":{"GSM":["GSM9553468","GSM9553467","GSM9553466","GSM9553465","GSM9553464","GSM9553463"],"GPL":["21290"],"GSE":["322507"],"taxon":["Homo sapiens"]}}